OSAKA, Japan & SAN DIEGO & SEATTLE–(BUSINESS WIRE)– Takeda Pharmaceutical Company Limited (“Takeda”) (TOKYO:4502) and PvP Biologics, Inc. (“PvP”) today announced a global agreement for the development of KumaMax, a novel enzyme designed to break …
( read original story …)